Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Laser Assisted vs Intradermal Influenza Vaccine
NCT02988739Phase 1Completed
- Sponsor
- Pantec Biosolutions AG
- Start
- Feb 2017
- Primary completion
- Jul 2017
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of IDflu in influenza (2 arms), sponsored by Pantec Biosolutions AG. Primary endpoints: Haemagglutination inhibition at Day 29 and Frequency of vaccine specific T-cell responders at Day 29. Started Feb 2017; status: completed.
02
Drugs
IDflu
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02988739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02988739.